Clinical TrialJun 9, 2026, 04:31 PM
Shattuck Labs Announces Positive SL-325 Phase 1 Data; Runway to 2029
AI Summary
Shattuck Labs announced positive Phase 1 clinical trial results for its lead DR3 blocking antibody, SL-325. The trial demonstrated a favorable safety profile, low immunogenicity with only 3.7% of participants developing anti-drug antibodies, and durable receptor occupancy supporting potential quarterly dosing. The company also provided an update on its pipeline, including the expected initiation of the RECEPTIVE-CD1 Phase 2b trial for SL-325 in Crohn's disease in Q3 2026 and an anticipated IND filing for SL-846 in the first half of 2027. Additionally, Shattuck expects to receive approximately $54.9 million from warrant exercises, extending its cash runway into 2029.
Key Highlights
- SL-325 Phase 1 trial showed 3.7% incidence of anti-drug antibodies (ADA) with low titers and no impact on PK or receptor occupancy.
- Complete DR3 occupancy observed at doses of 0.1 mg/kg and higher, with durable inhibition of TL1A binding for over 3 months at doses of 1 mg/kg and higher.
- SL-325 was well-tolerated with a favorable safety profile, with no serious treatment-emergent adverse events reported.
- The RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease is expected to initiate in Q3 2026.
- IND filing for SL-846 (DR3xIL-23R bispecific) is expected in the first half of 2027.
- Shattuck expects to fund operations into 2029 with approximately $145.3 million in cash and cash equivalents after warrant exercises.
Price Impact
More from STTK